AC Immune Reports Third Quarter 2018 Financial Results and Corporate Update
(WorldNews Switzerland)

Announced important clinical milestones for ACI-24 vaccine in Alzheimer`s disease and Down Syndrome Company record high, period end cash position of approximately CHF 200 million that is expected to extend our cash runway to Q3 2021, excluding potential incoming milestones Successfully issued 10 million new shares via three offerings to raise gross proceeds of USD 117.5 (CHF 116.3) million Lausanne, Switzerland, November 13, 2018 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced financial results for the three and nine months ended September 30, 2018. Prof. Andrea Pfeifer, CEO of...